New med-tech investment firm Vensana Capital reported Wednesday that it has closed an inaugural fund, Vensana Capital I, with $225 million in committed capital. The venture capital and growth equity investment firm, launched earlier this year, aims to use the fund to invest in 10 to 12 companies, with commitment sizes ranging from $10 million to $30 million per company.

The fund, which was oversubscribed, will focus on companies across the med-tech sector, including medical devices, diagnostics and information systems, digital health, drug delivery and technology-enabled services. Vensana does not plan to invest in biopharma ventures.

Tokyo-based Terumo Corp. already had a formal limited partner relationship with one U.S. venture firm, early medical device-focused, Mountain View, Calif.-based Emergent Medical Partners (EMP) that dates to 2013. Now it has added investment in two more venture firms, Santa Clara, Calif.-based Strategic Healthcare Investment Partners and Boston-based Catalyst Health Ventures.

Artificial intelligence (AI) has helped the med-tech industry in numerous ways. From genomics, to screening, to diagnostics, AI has made things easier for clinicians.

And that has caught the eye of investors. According to Mercom Capital Group LLC, as a whole, digital health venture capital funding in the second quarter 2019 jumped from the previous quarter ($3.1 billion raised in 169 deals vs. $2 billion raised in 149 deals).